163 related articles for article (PubMed ID: 34847263)
21. Preoperative abdominal fat distribution and systemic immune inflammation were associated with response to intravesical Bacillus Calmette-Guerin immunotherapy in patients with non-muscle invasive bladder cancer.
Ke ZB; Chen H; Chen JY; Cai H; Lin YZ; Sun XL; Huang JB; Zheng QS; Wei Y; Xue XY; Xu N
Clin Nutr; 2021 Dec; 40(12):5792-5801. PubMed ID: 34775222
[TBL] [Abstract][Full Text] [Related]
22. Estimated Costs and Long-term Outcomes of Patients With High-Risk Non-Muscle-Invasive Bladder Cancer Treated With Bacillus Calmette-Guérin in the Veterans Affairs Health System.
Williams SB; Howard LE; Foster ML; Klaassen Z; Sieluk J; De Hoedt AM; Freedland SJ
JAMA Netw Open; 2021 Mar; 4(3):e213800. PubMed ID: 33787908
[TBL] [Abstract][Full Text] [Related]
23. Impact of sex on response to BCG in non-muscle invasive bladder cancer patients: a contemporary review from a tertiary care center.
Bree KK; Hensley PJ; Brooks N; Matulay J; Nogueras-Gonzalez GM; Navai N; Dinney CP; Kamat AM
World J Urol; 2021 Nov; 39(11):4143-4149. PubMed ID: 34117914
[TBL] [Abstract][Full Text] [Related]
24. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer.
Arends TJ; Nativ O; Maffezzini M; de Cobelli O; Canepa G; Verweij F; Moskovitz B; van der Heijden AG; Witjes JA
Eur Urol; 2016 Jun; 69(6):1046-52. PubMed ID: 26803476
[TBL] [Abstract][Full Text] [Related]
25. Association of Bacillus Calmette-Guerin shortages with bladder cancer recurrence: A single-center retrospective study.
Lee S; Lim B; You D; Hong B; Hong JH; Kim CS; Ahn H; Jeong IG
Urol Oncol; 2020 Nov; 38(11):851.e11-851.e17. PubMed ID: 32800440
[TBL] [Abstract][Full Text] [Related]
26. Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign.
Li R; Metcalfe MJ; Tabayoyong WB; Guo CC; Nogueras González GM; Navai N; Grossman HB; Dinney CP; Kamat AM
Eur Urol Oncol; 2019 May; 2(3):286-293. PubMed ID: 31200843
[TBL] [Abstract][Full Text] [Related]
27. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérin.
Cambier S; Sylvester RJ; Collette L; Gontero P; Brausi MA; van Andel G; Kirkels WJ; Silva FC; Oosterlinck W; Prescott S; Kirkali Z; Powell PH; de Reijke TM; Turkeri L; Collette S; Oddens J
Eur Urol; 2016 Jan; 69(1):60-9. PubMed ID: 26210894
[TBL] [Abstract][Full Text] [Related]
28. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update.
Babjuk M; Burger M; Compérat EM; Gontero P; Mostafid AH; Palou J; van Rhijn BWG; Rouprêt M; Shariat SF; Sylvester R; Zigeuner R; Capoun O; Cohen D; Escrig JLD; Hernández V; Peyronnet B; Seisen T; Soukup V
Eur Urol; 2019 Nov; 76(5):639-657. PubMed ID: 31443960
[TBL] [Abstract][Full Text] [Related]
29. Editorial Comment from Dr Matsumoto to Real-world treatment patterns and clinical outcomes of Japanese patients with non-muscle invasive bladder cancer receiving intravesical bacillus Calmette-Guérin treatment.
Matsumoto K
Int J Urol; 2022 Oct; 29(10):1130-1131. PubMed ID: 35686305
[No Abstract] [Full Text] [Related]
30. Recurrence Rate and Cost Consequence of the Shortage of Bacillus Calmette-Guérin Connaught Strain for Bladder Cancer Patients.
Ourfali S; Ohannessian R; Fassi-Fehri H; Pages A; Badet L; Colombel M
Eur Urol Focus; 2021 Jan; 7(1):111-116. PubMed ID: 31005491
[TBL] [Abstract][Full Text] [Related]
31. Impact of carcinoma in situ on the outcome of intravesical Bacillus Calmette-Guérin therapy for non-muscle-invasive bladder cancer: a comparative analysis of large real-world data.
Tomida R; Miyake M; Minato R; Sawada Y; Matsumura M; Iida K; Hori S; Fukui S; Ohyama C; Miyake H; Hongo F; Taoka R; Kobayashi T; Kojima T; Matsui Y; Nishiyama N; Kitamura H; Nishiyama H; Fujimoto K; Hashine K;
Int J Clin Oncol; 2022 May; 27(5):958-968. PubMed ID: 35142962
[TBL] [Abstract][Full Text] [Related]
32. Impact of prior intravesical bacillus Calmette-Guerin therapy on the effectiveness of pembrolizumab for patients with metastatic urothelial carcinoma.
Taoka R; Kobayashi T; Hidaka Y; Abe H; Ito K; Kojima T; Kato M; Kanda S; Hatakeyama S; Matsui Y; Matsushita Y; Naito S; Shiga M; Miyake M; Muro Y; Nakanishi S; Kato Y; Shibuya T; Hayashi T; Yasumoto H; Yoshida T; Uemura M; Kamiyama M; Morita S; Ogawa O; Nishiyama H; Kitamura H; Sugimoto M;
Urol Oncol; 2022 Mar; 40(3):107.e1-107.e9. PubMed ID: 34454824
[TBL] [Abstract][Full Text] [Related]
33. All High-Grade Ta Tumors Should Be Classified as High Risk: Bacillus Calmette-Guérin Response in High-Grade Ta Tumors.
Bree KK; Hensley PJ; Lobo N; Brooks NA; Nogueras-Gonzalez GM; Guo CC; Navai N; Grossman HB; Dinney CP; Kamat AM
J Urol; 2022 Aug; 208(2):284-291. PubMed ID: 35770498
[TBL] [Abstract][Full Text] [Related]
34. The Impact of Progression on Healthcare Resource Utilization and Costs Among Patients with High-Grade Non-Muscle Invasive Bladder Cancer After Bacillus Calmette-Guérin Therapy: A Retrospective SEER-Medicare Analysis.
Yang M; Georgieva MV; Bocharova I; Vembusubramanian M; Qian K; Guo A; Kamat AM
Adv Ther; 2021 Mar; 38(3):1584-1600. PubMed ID: 33543424
[TBL] [Abstract][Full Text] [Related]
35. Safety and efficacy of intensive instillation of low-dose pirarubicin vs. bacillus Calmette-Guérin in patients with high-risk non-muscle-invasive bladder cancer.
Fujita N; Hatakeyama S; Momota M; Kido K; Narita T; Tobisawa Y; Yoneyama T; Yamamoto H; Imai A; Ito H; Yoneyama T; Hashimoto Y; Yoshikawa K; Ohyama C
Urol Oncol; 2020 Aug; 38(8):684.e17-684.e24. PubMed ID: 32278732
[TBL] [Abstract][Full Text] [Related]
36. Editorial Comment from Dr Taoka and Dr Sugimoto to Real-world treatment patterns and clinical outcomes of Japanese patients with non-muscle invasive bladder cancer receiving intravesical bacillus Calmette-Guérin treatment.
Taoka R; Sugimoto M
Int J Urol; 2022 Oct; 29(10):1130. PubMed ID: 35690471
[No Abstract] [Full Text] [Related]
37. Clinical outcomes after intravesical bacillus Calmette-Guérin for the highest-risk non-muscle-invasive bladder cancer newly defined in the Japanese Urological Association Guidelines 2019.
Miyamoto T; Miyake M; Toyoshima Y; Fujii T; Shimada K; Nishimura N; Iida K; Nakahama T; Hori S; Gotoh D; Nakai Y; Torimoto K; Tanaka N; Ohbayashi C; Fujimoto K
Int J Urol; 2021 Jul; 28(7):720-726. PubMed ID: 33734503
[TBL] [Abstract][Full Text] [Related]
38. Bacillus Calmette-Guérin (BCG) unresponsive non-muscle-invasive bladder cancer: are the subgroups equal?
Tan WS; Grajales V; Bree K; Li R; Nogueras-Gonzalez GM; Navai N; Dinney C; Kamat AM
BJU Int; 2023 Oct; 132(4):384-386. PubMed ID: 37246493
[No Abstract] [Full Text] [Related]
39. A Phase 1/2 Single-arm Clinical Trial of Recombinant Bacillus Calmette-Guérin (BCG) VPM1002BC Immunotherapy in Non-muscle-invasive Bladder Cancer Recurrence After Conventional BCG Therapy: SAKK 06/14.
Rentsch CA; Thalmann GN; Lucca I; Kwiatkowski M; Wirth GJ; Strebel RT; Engeler D; Pedrazzini A; Hüttenbrink C; Schultze-Seemann W; Torpai R; Bubendorf L; Wicki A; Roth B; Bosshard P; Püschel H; Boll DT; Hefermehl L; Roghmann F; Gierth M; Ribi K; Schäfer S; Hayoz S
Eur Urol Oncol; 2022 Apr; 5(2):195-202. PubMed ID: 35012889
[TBL] [Abstract][Full Text] [Related]
40. Outcomes of bacillus Calmette-Guérin therapy without a maintenance schedule for high-risk non-muscle-invasive bladder cancer in the second transurethral resection era.
Kikuchi H; Abe T; Matsumoto R; Osawa T; Maruyama S; Murai S; Shinohara N
Int J Urol; 2022 Mar; 29(3):251-258. PubMed ID: 34894009
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]